No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract Phase 2 trial shows umbralisib is safe and effective in patients with chronic lymphocytic leukemia who are intolerant to BTK or PI3Kδ inhibitor therapy

byKathleen Lau

June 4, 2021

in StudyGraphics

RELATED REPORTS

Tumour microenvironment factors may influence cancer progression and response to tamoxifen (Nolvadex) in patients with estrogen receptor-positive and human epidermal growth factor receptor 2 breast cancer

Younger age and systemic metastases may independently predict survival among patients with choroidal metastases

A digital mental health intervention may improve anxiety in breast cancer survivors

Image-guided salvage radiotherapy improves outcomes in patients with prostate cancer

RelatedReports

Variability in interpretation of breast biopsy slides associated with low verification of atypia and ductal carcinoma in situ

Chronic Disease

Tumour microenvironment factors may influence cancer progression and response to tamoxifen (Nolvadex) in patients with estrogen receptor-positive and human epidermal growth factor receptor 2 breast cancer

August 13, 2026

Adalimumab aids in control of noninfectious uveitis

Chronic Disease

Younger age and systemic metastases may independently predict survival among patients with choroidal metastases

August 3, 2026

Chronic Disease

A digital mental health intervention may improve anxiety in breast cancer survivors

July 31, 2026

Radiation plus hormone therapy may improve prostate cancer survival

Chronic Disease

Enzalutamide (Xtandi) and abiraterone (Zytiga) may have similar effectiveness in metastatic castration-sensitive prostate cancer

July 22, 2026

Rivaroxaban likely reduces risk of recurrent stroke in specific subgroup of patients with embolic stroke of undetermined source

Early initiation of rhythm-control for atrial fibrillation associated with lower risk of adverse cardiovascular outcomes

Delaying intrathecal therapy in leukemia may preclude need for cranial radiotherapy

Vemurafenib plus rituximab associated with complete response in refractory hairy-cell leukemia

Patient Basics: Middle-Ear Infection (Otitis Media)

Tympanostomy tubes not superior to medical management for recurrent acute otitis media

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

No Result

View All Result